Author: OurCrowd

[ThetaRay in PR Newswire] ThetaRay’s Industry-Leading Anti-Money Laundering (AML) Solution for Cross-Border Payments Now Cloud-Based

Apr 26, 2021 |

NEW YORK and LONDON and TEL AVIV, Israel, April 26, 2021 /PRNewswire/ — ThetaRay, a leading provider of AI-based Big Data analytics, today announced that its AML (Anti-Money Laundering) for Cross-Border Payments solution is now available as a cloud-based service. The cloud-agnostic offering protects banks, fintechs, PSPs and payments infrastructure companies from sophisticated money laundering schemes hidden within cross-border transactions, decreases total cost of ownership (TCO), provides the ability to increase revenues quickly, and shortens time-to-value from 6+ months to days. Read more...

Read More

[Perception Point in CTech] Bank Hapoalim to launch new investment track for startups

Apr 25, 2021 |

Bank Hapoalim over recent months has invested in three different Israeli startups as part of the Israel Innovation Authority’s (IIA) amendment 43 under which the state provides a return of up to 40% of the original investment in case of losses incurred, Calcalist has learned. The investments are being implemented via the bank’s Innovation and Strategy department led by Avivit Bender, who serves as the Chief Corporate Development and Fintech Officer at the bank. Read...

Read More
Newsletter: New drug discovery

Newsletter: New drug discovery

Apr 25, 2021 |

CytoReason: Helping Pfizer develop new drugs OurCrowd, Israel’s most active venture investor Will manufacturing eat the world? Memic raises $96M for robot-assisted surgery Bizzabo’s rollercoaster pivot to success DouxMatok rolls out low-sugar spreads in US SaNOtize seeks partner to help India against Covid-19 BioCatch adds to protection for financial transaction Introductions More than 1,000 high-tech jobs Startup of the Week: CytoReason: Helping Pfizer develop new drugs CytoReason is poised to earn at least $10M from Pfizer as the pharma giant uses the startup’s technology to produce the next generation of drugs more efficiently and effectively – whether it’s a booster shot against the novel coronavirus or an entirely new class of drugs. It can cost $400M to develop a single drug, and 90% of drugs in R&D fail. CytoReason uses AI technology to stimulate drug discovery and development, aggregating proprietary data from pharmaceutical companies across the industry to train its computational models of human disease. “We are getting to the point that computer models of certain diseases can generate better predictions than animal models,” CytoReason CEO David Harel tells...

Read More